Z. Younossi, Q. M. Anstee, and M. Marietti, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, vol.15, pp.11-20, 2018.

C. Estes, Q. M. Anstee, and M. T. Arias-loste, United Kingdom, and United States for the period 2016-2030, J Hepatol, 2018.

V. Rottiers and A. M. Naar, MicroRNAs in metabolism and metabolic disorders, Nat Rev Mol Cell Biol, vol.13, pp.239-50, 2012.

S. Bandiera, S. Pfeffer, and T. F. Baumert, miR-122-a key factor and therapeutic target in liver disease, J Hepatol, vol.62, pp.448-57, 2015.

H. L. Janssen, H. W. Reesink, and E. J. Lawitz, Treatment of HCV infection by targeting microRNA, N Engl J Med, vol.368, pp.1685-94, 2013.

M. H. Van-der-ree, J. M. De-vree, and F. Stelma, Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial, Lancet, vol.389, pp.709-726, 2017.

J. Krutzfeldt, N. Rajewsky, and R. Braich, Silencing of microRNAs in vivo with 'antagomirs', Nature, vol.438, pp.685-694, 2005.

C. Esau, S. Davis, and S. F. Murray, miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, Cell Metab, vol.3, pp.87-98, 2006.

J. Elmen, M. Lindow, and S. Schutz, LNA-mediated microRNA silencing in non-human primates, Nature, vol.452, pp.896-905, 2008.

S. H. Hsu, B. Wang, and J. Kota, Essential metabolic, antiinflammatory, and anti-tumorigenic functions of miR-122 in liver, J Clin Invest, vol.122, pp.2871-83, 2012.

W. C. Tsai, S. D. Hsu, and C. S. Hsu, MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis, J Clin Invest, vol.122, pp.2884-97, 2012.

C. Coulouarn, V. M. Factor, and J. B. Andersen, Loss of miR122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties, Oncogene, vol.28, pp.3526-3562, 2009.

A. Satishchandran, A. Ambade, and S. Rao, Regulated by GRLH2, Protects Livers of Mice and Patients From Ethanol-Induced Liver Disease, Gastroenterology, vol.122, pp.238-52, 2018.

C. Chai, M. Rivkin, and L. Berkovits, Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues, Gastroenterology, vol.153, pp.1404-1419, 2017.

S. Sakata, T. Komaki, and N. Kojima, Dynamics of plasma lipoproteins and lipids during double filtration plasmapheresis (DEP), Jpn J Med, vol.26, pp.176-185, 1987.

X. Chen, H. Liang, and J. Zhang, Horizontal transfer of microRNAs: molecular mechanisms and clinical applications, Protein Cell, vol.3, pp.28-37, 2012.

K. Zhang, L. Li, and Y. Qi, Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice, Endocrinology, vol.153, pp.631-677, 2012.

F. Wang, S. E. Mullican, and J. R. Dispirito, Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARgamma, Proc Natl Acad Sci U S A, vol.110, pp.18656-61, 2013.

K. Kim, K. Boo, and Y. S. Yu, RORalpha controls hepatic lipid homeostasis via negative regulation of PPARgamma transcriptional network, Nat Commun, vol.8, p.162, 2017.

H. Xu, J. H. He, and Z. D. Xiao, Liver-enriched transcription